<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">Favipiravir (FPV), a derivative of pyrazine carboxamide, is a promising broad-spectrum antiviral drug initially developed for influenza several years ago. It acts by preventing the influenza viral RNA-dependent polymerase RNA, thus blocking the replication process by acting negatively on genetic copying. It has been screened against many RNA viruses including H1N1, Ebola, Arena virus, and Bunyavirus because of its action against RNA viruses. It was however approved in Japan and France and not in other countries for a few indications [
 <xref rid="bb0535" ref-type="bibr">107</xref>].
</p>
